John K Eldredge

Title: John K Eldredge: Innovator in Fc-Binding Polypeptide Variants

Introduction

John K Eldredge is a notable inventor based in South Chatham, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of polypeptide variants that bind to the neonatal Fc receptor (FcRn). His work has implications for therapeutic applications, enhancing the understanding of effector functions mediated by Fc-containing polypeptides.

Latest Patents

John K Eldredge holds a patent for "Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto." This invention is based on the discovery that the effector function of an Fc-containing polypeptide can be modified by altering specific amino acid residues. The polypeptides generated through this method are highly variable and can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof. He has 1 patent to his name.

Career Highlights

Eldredge is associated with Biogen Idec MA Inc., a leading biotechnology company known for its innovative therapies. His work at Biogen has allowed him to contribute to advancements in the understanding of immune responses and therapeutic development.

Collaborations

Throughout his career, John K Eldredge has collaborated with esteemed colleagues such as Graham K Farrington and Alexey Alexandrovich Lugovskoy. These collaborations have fostered a productive environment for innovation and research in the field of biotechnology.

Conclusion

John K Eldredge's contributions to the field of biotechnology, particularly through his patent on Fc-binding polypeptide variants, highlight his role as an innovator. His work continues to influence therapeutic strategies and enhance our understanding of immune functions.